30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

2014 Revenue: Amedica

4Q14 revenue: $5.2MM (Silicon Nitride/SiNi revenue +22%)

2014 revenue: $22.8MM, +2% (SiNi $10.8MM, +41%; Metals flat)


  • Excluding biologics in 2014 and 2013, revenue +12%
  • Estimates U.S. and EU spinal interbody market of ~$2BB
  • Interim results from CASCADE clinical trial indicate that SiNi composite interbody spinal devices alone, without bone graft or synthetic bone void filler, achieved similar fusion rates and clinical scores as patients implanted with traditional spacers using autograft
  • Completed enrollment in SNAP (Silicon Nitride and PEEK) trial, comparing 1st gen lumbar SiNi devices to PEEK; 1-year follow-up data expected in 1Q16
  • JAX trial on hold in favor of other trials with different hypotheses that arise from CASCADE data
  • Received ANVISA clearance of 1st-gen Valeo devices in Brazil
  • Plans to update metals business in 2015